Genocea Commences Phase 2a Trial for GEN-004, Universal Pneumococcal Vaccine Candidate

September 11, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced the initiation of a Phase 2a trial for GEN-004, the Company’s universal vaccine candidate against pneumococcus. The trial is designed to evaluate the effect of dosing with GEN-004 on the frequency, magnitude and duration of colonization by pneumococcus in the nasopharynx of …

Genocea Presents Phase 1 Immunology Data for Novel Pneumoccocus Vaccine at ICAAC

GEN-004 Shown to Induce Antibody and TH17 Responses September 6, 2014 Genocea Biosciences, Inc., a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today presented data from a Phase 1 study of GEN-004, an investigational vaccine designed to prevent disease caused by all serotypes of pneumococcus (Streptococcus pneumoniae) The poster (G-291), titled “Safety and Immunogenicity of a Novel Lipidated Protein …

Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects

Immunogenicity Data from Phase 1/2a Trial Highlighted at 39th Annual International Herpesvirus Workshop July 22, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above …

Genocea Commences Phase 2 Dose Optimization Trial for GEN-003 HSV-2 Immunotherapy

July 21, 2014 Genocea Biosciences, Inc., a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced the start of a Phase 2 dose optimization trial for GEN-003, the Company’s immunotherapy candidate against herpes simplex-type 2 (HSV-2). “Consistent with our long-standing development plans, this Phase 2 trial will compare the best dose of GEN-003 from our Phase 1/2a trial …